secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021367
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q1 net loss narrows to $28.4M; cash $299M into 2027; Biogen milestone $8M, Merck deal up to $740M
--------------------------------------------------------------------------------

- Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.
- Cash $299.2M as of Mar 31; expected runway into 2027.
- Earned $8M from Biogen; Merck KGaA collaboration with $16M upfront and up to $740M milestones.
- Phase 1 trials for cemsidomide (MM/NHL) and CFT1946 (solid tumors) progressing; data expected 2H 2024.
- Appointed Dan Powers as SVP clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/0001628280-24-021367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024021367/cccc-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer